YFYanchun Feng

Yanchun Feng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yanchun Feng has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Cuicui Sun

    Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China

    2 shared publications
  • Dian Xiao

    National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China

    2 shared publications
  • Hongbin Deng

    Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    2 shared publications
  • Jingwen Dong

    Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China

    2 shared publications
  • Mingxiao Yin

    Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China

    2 shared publications
  • Xinbo Zhou

    National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China

    2 shared publications

Latest Publications

  • Open Access

    Standardization of determination of correction factor by HPLC slope method using impurities in Fluconazole API and dosage forms

    by Ting Xiao, Xiaoxu Li, Wenli Pei, Xuan Jin, Yanchun Feng

    HPLC slope method is classical for determining impurity correction factor (CF). However, some key parameters of this method haven't been unified. In this study, the selection of three key parameters was explored, namely Parameter I: the concentration range of the calibration curve, Parameter II: the number of data points to establish calibration curve and, Parameter III: Whether the intercept of the calibration curve is retained or not. Parameter I was designed three levels: the impurity LOQ to 150% of the impurity limit, the impurity LOQ to the API determination concentration, and 80%–120% of the API determination concentration; Parameter II was designed four levels: 3, 5, 7 and 9 points, and Parameter III was designed two levels: intercept retention or not. As an example, Fluconazole API and its six impurities (A, B, C, D, F and I) were analyzed. Using the within-group design of multi-factors, the CF of each impurity was determined at all levels of different parameter combination. In addition, the effects of four factors on CF determination, namely, detection wavelength, column, column temperature and flow rate, were investigated, and the PBD method in the DoE screening experiment was used to design the experimental protocol. The results showed that when the concentration range from the impurity LOQ to 150% of the impurity limit meets the linearity requirement, it is reasonable to select 5 points within the range to establish the fitting equation and calculate the CF, and there is no need to process the intercept. The CF is a constant related to the detection wavelength, and when the distance between the UV spectra of impurity and API is small, a small change in wavelength may have a significant effect on the determination of the CF. However, the flow rate, column and column temperature have no significant effects.

  • Open Access

    Daurisoline Modulates the TBK1-Dependent Type I Interferon Pathway to Boost Anti-tumor Immunity via Targeting of LRP1

    by Borui Tang, Yuting Wang, Liping Li, Cuicui Sun, Jingwen Dong, Ruoqi Li, Jianfeng Wang, Yu Long, Mingxiao Yin, Fei Xie, et al.

    A promising therapeutic approach in oncology involves immune checkpoint blockade (ICB), which stimulates anti-tumor immune responses. Nevertheless, the effectiveness of this treatment in clinical settings remains limited, underscoring the need for complementary strategies. Recent studies highlight the potential of type I interferon (IFN-I) inducers to reprogram the tumor microenvironment and enhance ICB outcomes. Herein, through high-content screening of a natural compound library, we identified daurisoline (DS), a bioactive alkaloid extracted from the Chinese herbal medicine Rhizoma Menispermi, as a potent inducer of IFN-I signaling. Our findings indicated that DS up-regulates interferon responses and pro-inflammatory cytokine expression in a TANK-binding kinase 1 (TBK1)-dependent manner. In vivo, DS exhibited marked tumor growth inhibition by activating dendritic cells, macrophages, and CD8 + T cells, thereby enhancing anti-tumor immunity. Utilizing the LiP-SMap approach, we identified low-density lipoprotein receptor-related protein 1 (LRP1) as the direct target of DS. Mechanistically, the binding of DS to LRP1 substantially disrupted lysosomal function, which subsequently triggered 5′-azacytidine-induced protein 2-mediated TBK1 activation and IFN-I production. Furthermore, DS demonstrated synergistic effects with anti-programmed death 1 therapy and a stimulator of interferon genes agonist by remodeling the immunosuppressive microenvironment. Collectively, our findings establish LRP1 as a novel therapeutic target for cancer immunotherapy and highlight DS-driven immune reprogramming as a translatable strategy to potentiate ICB efficacy.


  • USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1

    by Zean Kuang, Xiaojia Liu, Na Zhang, Jingwen Dong, Cuicui Sun, Mingxiao Yin, Yuting Wang, Lu Liu, Dian Xiao, Xinbo Zhou, et al.

    The abnormal upregulation of programmed death ligand-1 (PD-L1) on tumor cells impedes T-cell mediated cytotoxicity through PD-1 engagement, and further exploring the mechanisms regulation of PD-L1 in cancers may enhance the clinical efficacy of PD-L1 blockade. Here, using single-guide RNAs (sgRNAs) screening system, we identify ubiquitin-specific processing protease 2 (USP2) as a novel regulator of PD-L1 stabilization for tumor immune evasion. USP2 directly interacts with and increases PD-L1 abundance in colorectal and prostate cancer cells. Our results show that Thr288, Arg292 and Asp293 at USP2 control its binding to PD-L1 through deconjugating the K48-linked polyubiquitination at lysine 270 of PD-L1. Depletion of USP2 causes endoplasmic reticulum (ER)-associated degradation of PD-L1, thus attenuates PD-L1/PD-1 interaction and sensitizes cancer cells to T cell-mediated killing. Meanwhile, USP2 ablation-induced PD-L1 clearance enhances antitumor immunity in mice via increasing CD8+ T cells infiltration and reducing immunosuppressive infiltration of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), whereas PD-L1 overexpression reverses the tumor growth suppression by USP2 silencing. USP2-depletion combination with anti-PD-1 also exhibits a synergistic anti-tumor effect. Furthermore, analysis of clinical tissue samples indicates that USP2 is positively associated with PD-L1 expression in cancer. Collectively, our data reveal a crucial role of USP2 for controlling PD-L1 stabilization in tumor cells, and highlight USP2 as a potential therapeutic target for cancer immunotherapy.


  • Open Access

    Identification of Multi-Class Drugs Based on Near Infrared Spectroscopy and Bidirectional Generative Adversarial Networks

    by Anbing Zheng, Huihua Yang, Xipeng Pan, Lihui Yin, Yanchun Feng

    Drug detection and identification technology are of great significance in drug supervision and management. To determine the exact source of drugs, it is often necessary to directly identify multiple varieties of drugs produced by multiple manufacturers. Near-infrared spectroscopy (NIR) combined with chemometrics is generally used in these cases. However, existing NIR classification modeling methods have great limitations in dealing with a large number of categories and spectra, especially under the premise of insufficient samples, unbalanced samples, and sensitive identification error cost. Therefore, this paper proposes a NIR multi-classification modeling method based on a modified Bidirectional Generative Adversarial Networks (Bi-GAN). It makes full utilization of the powerful feature extraction ability and good sample generation quality of Bi-GAN and uses the generated samples with obvious features, an equal number between classes, and a sufficient number within classes to replace the unbalanced and insufficient real samples in the courses of spectral classification. 1721 samples of four kinds of drugs produced by 29 manufacturers were used as experimental materials, and the results demonstrate that this method is superior to other comparative methods in drug NIR classification scenarios, and the optimal accuracy rate is even more than 99% under ideal conditions.